ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

OPTI Optibiotix Health Plc

18.00
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 18.00 17.50 18.50 18.00 18.00 18.00 66,018 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Noncomml Resh Organizations 457k 2.59M 0.0284 6.34 16.41M
Optibiotix Health Plc is listed in the Noncomml Resh Organizations sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix Health was 18p. Over the last year, Optibiotix Health shares have traded in a share price range of 5.75p to 43.50p.

Optibiotix Health currently has 91,190,661 shares in issue. The market capitalisation of Optibiotix Health is £16.41 million. Optibiotix Health has a price to earnings ratio (PE ratio) of 6.34.

Optibiotix Health Share Discussion Threads

Showing 50226 to 50245 of 147575 messages
Chat Pages: Latest  2015  2014  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004  Older
DateSubjectAuthorDiscuss
21/3/2019
10:07
Grow up sunshine.
scotty1
20/3/2019
22:33
Quite the reverse aspex. That’s why you have a 6% spread, not all are gullible out there!
rayrac
20/3/2019
18:05
That really is some list, Parob. Thanks for keeping tabs as ever.
colinzeal
20/3/2019
17:44
Incredible 6 percent spread at the close with very low turnover just indicates that the broad understanding of today's deal by your average punter is not there.
aspex
20/3/2019
17:31
Updated list following today's deal.Recent, current and potential future revenue streams confirmed:- GoFigure: shakes, bars and muesli pots - CholBiome (x3 and Daily Maintenance)- Sacco/CSL - HLH BioPharma Vertriebs GmbH - Nutrilinia (LD-LDL and Slimbiome Medical)- Pharmabiota- Galenicum Special Ingredients - Knighton Foods- Cereal Ingredients Inc.- Fine Foods & Pharmaceuticals- Trigen Pharma- Cambridge Commodities - Akums Drugs and Pharma- Seed Health- John Morley's - Alfasigma- Unnamed global corporate ($100B+ turnover) for SweetBiotix manufacturing & distribution.- Unnamed US pharma partner (cholesterol strain)- Bened Biomedical- Bulgarian CholBiome distributor (Velinoff Pharma/Medochem)- CTC Group- Formulation Creations- US Pharma Lab Inc.- Unnamed Greece and Cyprus CholBiome distributor- Unnamed Greece and Cyprus SlimBiome Medical distributor - Zeon Lifesciences - SilvExpo - CholBiome- Biolat - RMS CardioPro- EIWA Trading Co. Ltd- DKSHRevenue not confirmed yet:- Tata X 2 (Slimbiome and LPGOS)- Mystery US Slimbiome customer- Paradise Fruits (Slimbiome)- Beijing Duoite Biotechnology Co., Ltd (LP-LDL distributors via CSL)Products on the market already but not RNSed:- MuscleForm (Aviform Ltd) - Ultra MR Ultimate Meal Replacement - Olliscience - Ollibiotic - Aragan - Biotic•P3- 39ytu - Capsa Food
parob
20/3/2019
15:58
I think the clue is in the rns which reads " market exclusivity is linked to sales orders".
1bokke
20/3/2019
15:08
Anyone know if it’s just Gofigure or if it also involves Slimbiome Medical for this deal?
imnotlong
20/3/2019
14:17
I asked Stephen O'Hara, CEO of the OptiBiotix, if today's announcement is purely B2c via a B2B partnership, and not related to establishing new products and if so, is it safe to assume revenues, sales should be pretty quick, perhaps as quick as H2 this year? Essentially, this agreement takes GoFigure products to a new much bigger level via a partner that has already established partnerships within the consumer market, meaning the typical 9-12 months each B2B deal takes to establish a product from scratch is not the case because this agreement is for existing SlimBiome products.

Stephen O'Hara: "Yes. I have built into the agreement a requirement for orders within the financial year. They are a big company with a big network so should be good."

scotty1
20/3/2019
13:33
Rayrac so in your opinion best for companies not to do any deal big companies,good logic there NOT
scotty1
20/3/2019
13:31
Yes seen that over on LSE rafboy

Todays London MetroToday 09:58Big Full Page Article on Go Figure - Don't Yo-Yo, give science a go.

scotty1
20/3/2019
13:27
Another advertorial in METRO today I am told. Not seen myself.
rafboy
20/3/2019
13:23
Another advertorial in METRO today I am told.
rafboy
20/3/2019
13:22
He’s right. Can’t see any logic in the deal for opti...they’ve got Opti by the short and curlies. If Opti got more than 1% out of it, I’d be amazed.
rayrac
20/3/2019
12:49
mike with all due respect you bought in and didn't even know who SoH was/is so not much research there mate 😒

mikethebike4 11 Mar '19 - 17:29 - 47322 of 47591
0 1 0
who is SoH ?

scotty1
20/3/2019
12:22
Nobbygnome

'This deals highlights the elegant business model. A big deal with just one of the product areas in big countries with a company which is big in those countries. The exponential growth of revenues is bound to follow with this approach.'

See Futura Medical (FUM)for a company with the above philosophy and look where it has got them after 17 years

You are entirely in the hands of the 'big company' - even if they want to suppress your product for any reason ! - they obviously don't mention this when doing the original deal

mikethebike4
20/3/2019
11:40
Parob, agreed. The problem we have, is like risky pointed out with my hypothesis, we dont know at what rate revenues per deal are building, until we have an RNS with actual revenue figures we are stuck. I believe it's growing, but the market doesn't like the Adam Reynolds keyboard!
toyin
20/3/2019
11:33
The disconnect between deals/progress and share price won't last forever.All it is going to take is a large deal to break us out of this flag/trading range and we will be away.
parob
20/3/2019
11:29
risky, my £3.75m is looking better by the day!😉
toyin
20/3/2019
11:14
DKSH in Spain'DKSH Business Line Food & Beverage Industry is a leading food ingredients distributor and global provider of Market Expansion Services for business partners in the beverage, dairy, confectionery and bakery, nutritional supplements, processed food and food service industries.''We develop tailor-made new products, formulations and breakthrough applications in collaboration with our team of specialized staff from our dedicated award-winning innovation centers. Our market insight and broad overview enables us to scout for long-term trends in products and technology beyond short-lived fashions.''We provide all the required marketing and sales services as well as distribution and inbound logistics for companies lacking a global footprint. We have the capability to manage your entire supply chain, including import and export management, warehousing solutions and specialized services, such as labelling and invoicing.'Nice deal with a multi £bn corporate with a proven & established market penetration model. Goes to show what's going on in the background. https://dksh.com/es-en/home
riskybusiness1
20/3/2019
08:22
Worth notin g this distribution deal includes extg products so time to point of sales and revenues should be pretty fast.

I do like the mix of deals and revenues and sales targets set for partners.

A little patience when we are so close is all we need.

There’s been some notable restlessness here but nows the time to be brave whilst volumes are low and tax year end .

April should be a big month imo.

S

shrewdmole
Chat Pages: Latest  2015  2014  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004  Older

Your Recent History

Delayed Upgrade Clock